In this podcast, JAMA Deputy Editors Linda Brubaker, MD, and Preeti Malani, MD, MSJ, and Executive Editor Gregory Curfman, MD, discuss the latest science published in JAMA:
➡️ #Evolocumab for Reducing MACE,
➡️ #Lead Exposure and #CVD,
➡️ #AI Scribes for Clinicians, and more.
🎧 Listen now: https://ja.ma/3PPUVgm
💬 Viewpoint: Standardized coverage and incentives in the CMS BALANCE model may reduce prior authorization burden and financial barriers for novel #obesity medications, but broad program participation and persistence remain uncertain.
https://ja.ma/4tnOYWj
#AI scribe adoption across 5 academic centers was associated with modest reductions in EHR and documentation time, plus a slight increase in weekly visit volume, especially for primary care and female clinicians.
https://ja.ma/4mgJASQ
💬 Perspective: The dominance of EHR vendor #AI models may reduce incentives for innovation and diversity among third-party health AI tools, raising questions for policymakers.
https://ja.ma/482sQZF
📊 JAMA Clinical Guidelines Synopsis: The 2024 guideline from the @American_Heart and @ACCinTouch recommends continuing statins and β-blockers for patients undergoing noncardiac surgery.
https://ja.ma/4mbExmx
Patients with decompensated #Cirrhosis who abstain from alcohol may achieve liver recovery, with improved prognosis linked to early cessation and fewer complications.
JAMA Medical News Director Jennifer Abbasi and Associate Managing Editor Kate Schweitzer discuss how early alcohol cessation, fewer complications, and hepatic inflammation are linked to improved outcomes.
🎧 Listen now: https://ja.ma/4sXBnW0
Med News: New research highlights the potential for liver recovery in patients with alcohol-related decompensated cirrhosis who stop drinking.
https://ja.ma/4v0742i
Med News: In March, more than 50 US medical schools committed to boosting nutrition training under a new HHS initiative.
Experts welcome the push but say competencies should be evidence-based and realistic.
https://ja.ma/4mcakUv
How are vaccines evaluated after approval?
JAMA Statistical Editor Roger Lewis, MD, PhD, and Natalie Dean, PhD, explain the test-negative study design, highlighting its role in analyzing effectiveness and minimizing bias in observational studies.
🎧 Listen now: https://ja.ma/4toCZYH
#AI scribe adoption across 5 academic centers was associated with modest reductions in EHR and documentation time, plus a slight increase in weekly visit volume, especially for primary care and female clinicians.
https://ja.ma/417UZdQ
💬 Viewpoint: Standardized coverage and incentives in the CMS BALANCE model may reduce prior authorization burden and financial barriers for novel #obesity medications, but broad program participation and persistence remain uncertain.
https://ja.ma/48svk3p
At a $245/month price, the CMS BALANCE model could save Medicare nearly $933 million on #semaglutide in 2027, offsetting costs for up to 550 000 additional beneficiaries eligible for #obesity coverage.
https://ja.ma/47GVkYF
"As a mother and an obstetrician, these are the hardest rooms that I enter, the most difficult places that I hold in my heart."
In #APieceofMyMind, an obstetrician discusses the duality of joy and grief experienced in the labor and delivery unit. https://ja.ma/4c1dhT7
💬 Viewpoint: Standardized coverage and incentives in the CMS BALANCE model may reduce prior authorization burden and financial barriers for novel #obesity medications, but broad program participation and persistence remain uncertain.
https://ja.ma/4sf2sCJ
At a $245/month price, the CMS BALANCE model could save Medicare nearly $933 million on #semaglutide in 2027, offsetting costs for up to 550 000 additional beneficiaries eligible for #obesity coverage.
https://ja.ma/41NCFXu
💬 Viewpoint: Linking equity, patient-centeredness, and technical progress as interconnected goals—rather than isolated fixes—is required to transform US health care beyond incremental improvement.
https://ja.ma/4sQqS6S
💬 Perspective: The dominance of EHR vendor #AI models may reduce incentives for innovation and diversity among third-party health AI tools, raising questions for policymakers.
https://ja.ma/41Mbe0c
📊 JAMA Clinical Guidelines Synopsis: The 2024 guideline from the @American_Heart and @ACCinTouch recommends continuing statins and β-blockers for patients undergoing noncardiac surgery.
https://ja.ma/4doNg2u
💬 Editorial: Ambient #AI scribes reduce clinician documentation time and increase productivity, but evidence for their impact on patient outcomes and health equity remains limited.
https://ja.ma/4sM1rDu
#AI scribe adoption across 5 academic centers was associated with modest reductions in EHR and documentation time, plus a slight increase in weekly visit volume, especially for primary care and female clinicians.
https://ja.ma/3NzDzUo
💬 Viewpoint: Breast density increases cancer risk and reduces #Mammography sensitivity, but access to supplemental screening like #MRI and ultrasonography remains limited, creating disparities in early #BreastCancer detection.
https://ja.ma/4tqn3VX
📊 JAMA Clinical Guidelines Synopsis: The 2025 guideline for #ACS management recommends dual antiplatelet therapy with aspirin and a P2Y12 inhibitor, high-intensity statins, invasive revascularization, and radial access for angiography.
https://ja.ma/4scM1XL
Bone lead levels were directly associated with higher #CardiovascularDisease mortality, and lead was the eighth leading cause of death worldwide and second among environmental risks in 2023.
https://ja.ma/4sNQam6
In adults with moderate to severe #ARDS, inhaled sevoflurane sedation produced fewer ventilator-free days and lower 90-day survival than intravenous propofol, raising safety concerns including acute kidney injury.
🎥 Watch the video and read the full article: https://ja.ma/3NSEkYH
💬 Viewpoint: Linking equity, patient-centeredness, and technical progress as interconnected goals—rather than isolated fixes—is required to transform US health care beyond incremental improvement.
https://ja.ma/4bVU9Wx
💬 Perspective: The dominance of EHR vendor #AI models may reduce incentives for innovation and diversity among third-party health AI tools, raising questions for policymakers.
https://ja.ma/4sNCt6E
📊 JAMA Clinical Guidelines Synopsis: The 2024 guideline from the @American_Heart and @ACCinTouch recommends continuing statins and β-blockers for patients undergoing noncardiac surgery.
https://ja.ma/3NDhhRE
A new study shows that a targeted cholesterol-lowering therapy can prevent a first heart attack or stroke in high-risk patients with diabetes.
Read more from @MassGenBrigham researchers in @JAMA_current: https://www.massgeneralbrigham.org/en/about/newsroom/press-releases/cholesterol-lowering-therapy-for-heart-attack-stroke-prevention-diabetic-patients https://doi.org/10.1001/jama.2026.3277
Recent advances in the diagnosis and treatment of iron deficiency highlight its prevalence and health impact beyond #anemia.
JAMA Associate Editor Margaret Wheeler, MD, and Michael Auerbach, MD, clinical professor at Georgetown University, discussed updated strategies, at-risk populations, and effective management—including intravenous iron.
🎧 Listen now: https://ja.ma/41ABqLd
💬 Viewpoint: Breast density increases cancer risk and reduces #Mammography sensitivity, but access to supplemental screening like #MRI and ultrasonography remains limited, creating disparities in early #BreastCancer detection.
https://ja.ma/4814X4o
📊 JAMA Clinical Guidelines Synopsis: The 2025 guideline for #ACS management recommends dual antiplatelet therapy with aspirin and a P2Y12 inhibitor, high-intensity statins, invasive revascularization, and radial access for angiography.
https://ja.ma/4dc0QpH
R to @JAMA_current: 💬 Editorial: Phasing out leaded gasoline reduced #LeadExposure and #CoronaryHeartDisease mortality in high-income countries, but risk persists globally due to industrial emissions and resource gaps.
https://ja.ma/4ccdzaN
Bone lead levels were directly associated with higher #CardiovascularDisease mortality, and lead was the eighth leading cause of death worldwide and second among environmental risks in 2023. 🧵
https://ja.ma/4m4wMii
A JAMA study details how lead lingers in the body and how it can elevate blood pressure, harm blood vessel lining, and raise risk of heart attack. https://trib.al/DOAclTO
💬 Editor's Note by Véronique Kiermer, PhD, Chief Scientific Officer of @PLOS, Kirsten Bibbins-Domingo, PhD, MD, MAS, Editor in Chief of @JAMA_current and @JAMANetwork, and Magdalena Skipper, PhD, Editor in Chief of @Nature:
Responsible research authorship is anchored in credit, accountability, and transparency. Institutions and journals can provide stronger guidance and must work together to maintain integrity in authorship decisions.
https://ja.ma/4bYvgJX
#ResistantHypertension affects approximately 10% of patients treated for #hypertension and is associated with increased #cardiovascular mortality compared with controlled blood pressure.
📄 Learn more in this Review: https://ja.ma/4bExPSl
💬 Perspective: FDA removal of most black box warnings for #menopausal #HormoneTherapy enables individualized menopause symptom management; #estrogen-only therapy retains a warning for #endometrial cancer risk in women with a uterus.
https://ja.ma/4uZmnIB
📊 Research Summary: Higher doses of nalbuphine ER led to greater cough reduction in idiopathic pulmonary fibrosis; adverse events were consistent with those expected for opioid-class medications.
https://ja.ma/4cccTlP
Among women with #PSCAD, compared to #NPSCAD, rates of assisted reproductive technology use, #preeclampsia, #multigravidity, and severe acute #coronary events were higher; LVEF recovery was less likely at 1 year.
#ACC2026 @ACCinTouch
https://ja.ma/4sPOAzW
Extended low-dose #Apixaban reduced symptomatic #SuperficialVeinThrombosis risk among patients with provoked venous thromboembolism and enduring recurrence risk factors.
#ACC2026 @ACCinTouch
https://ja.ma/4sCPvnf